Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome Life Science Investing News
AGTC Announces Topline Interim Six-Month Data from Phase 1/2 X-Linked Retinoschisis Clinical Study Biotech Investing
Naturally Splendid Provides Expanded Distribution Update of HempOmega™ Infused Beers Cannabis Investing News
What Does Early Data from BriaCell’s Bria-IMT Combination Study with KEYTRUDA Show? Biotech Investing
DBV Technologies Highlights Data Supporting Induction of Immunotolerance Through the Skin at Inflammatory Skin Disease Summit 2018 Pharmaceutical Investing
XBiotech’s Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease Biotech Investing
Zosano Receives Conditional FDA Acceptance of Proposed Brand Name Qtrypta for M207 Pharmaceutical Investing
Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency Pharmaceutical Investing
